ArticleJA clinical reports2025
Ultrasound-guided serratus posterior superior muscle block for myofascial pain syndrome in the cervicoscapular region: a report of three cases.
Article in JA clinical reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThese case reports focus on successful pain management with ultrasound-guided serratus posterior superior muscle (SPSM) block using 30 mL of 0.25% ropivacaine or physiological saline in three myofascial pain syndrome (MPS) patients presented with cervicoscapular pain. CASE PRESENTATION: The SPSM block was administered to three ambulatory patients (cases #1, #2, and #3) who presented with cervicoscapular pain. The SPSM block with 30 mL of 0.25% ropivacaine drastically decreased an NRS score and provided 2-3 weeks of pain relief in cases #1 and #2. On the contrary, the SPSM block with 30 mL of physiological saline also mildly decreased an NRS score and provided 3 weeks of pain relief in cases #1 and #3.
conclusionsThe SPSM block using 30 mL of 0.25% ropivacaine or physiological saline successfully decreased the NRS scores in three MPS patients. These findings suggest that the SPSM block may serve as a useful therapeutic option in MPS patients presenting with cervicoscapular pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.